December 2, 2015
Ron Harrington named Horatio Alger Awardee.
September 30, 2015
OptiKira, a start-up biotechnology company, has been awarded two Small Business Technology Transfer (STTR) grants, one from the National Eye Institute (NEI) and one from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
September 21, 2015
BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development centered at University Hospitals in Cleveland, Ohio, announced today that it has entered into a strategic partnership with Biogen. This discovery collaboration will leverage the strengths of both organizations to identify pioneering neuroscience discoveries and advance them into medicines.
September 3, 2015
Search for new inflammatory disease and cancer drug targets aided by detailed structure.
August 26, 2015
The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio – part of The Harrington Project for Discovery & Development – has announced 2015 Harrington Scholars selected in collaboration with R&D partners University of Oxford, Alzheimer’s Drug Discovery Foundation (ADDF), and Foundation Fighting Blindness.
August 4, 2015
Harrington Scientific Director Mukesh Jain delivers 2015 American Society for Clinical Investigation Presidential Address.
August 3, 2015
2015 Harrington Prize awardee, Dr. Douglas Lowy, interviewed by ideastream’s Kay Colby to talk about the HPV vaccine, as well as other issues related to cancer research including funding challenges and disparities affecting racial and ethnic groups.
July 15, 2015
Case Western Reserve…found a new benefit of Kruppel-like Factor 15 (KLF15) -- keeping the body in metabolic balance… "It's important to understand how nutrients are acquired, how they are made available to tissues, how they are used, and how disease alters the dynamics of the process," said Mukesh K. Jain, MD, Ellery Sedgwick Jr. Chair & Distinguished Scientist and director of the Case Cardiovascular Research Institute, Case Western Reserve University School of Medicine. "The heart, for example, is a very energy-demanding organ that succumbs to failure if it has insufficient access to nutrients or fails to properly utilize nutrients." … "The beautiful aspect of this work is that nature designed this very clever molecule to regulate both nutrient availability and use, and the molecule functions broadly across all nutrient classes, which is very exciting. That's what makes it an important discovery," said Jain, also the scientific director of the Harrington Discovery Institute, chief research officer of the Harrington Heart & Vascular Institute, and chief scientific officer of University Hospitals Health System.
July 1, 2015
BioMotiv, LLC (“BioMotiv”) a drug development accelerator associated with The Harrington Project for Discovery & Development—centered at University Hospitals in Cleveland, Ohio—announces the formation of
Sujana Biotech, LLC, (“Sujana Biotech”) a company developing novel technologies and therapeutic products for a range of inflammatory and vascular disorders.
May 19, 2015
A physician-scientist at Oxford University in England is developing a first-of-its-kind therapy for Crohn’s disease with support from University Hospitals, 3,700 miles and an ocean away. This international collaboration reflects just one of many happenings in the breakout year of 2014 for the Harrington Discovery Institute at University Hospitals in Cleveland, Ohio – part of The Harrington Project for Discovery and Development.
March 13, 2015
University Hospitals announces that Mukesh K. Jain, MD, FAHA, has
been named Chief Scientific Officer for University Hospitals (UH).
March 3, 2015
The Harrington Discovery Institute (HDI) at University Hospitals (UH) in Cleveland, Ohio – part of The Harrington Project for Discovery & Development – has opened its annual award competition to fund and support physician-scientist innovators at major academic medical centers across the nation in their efforts to advance promising drug discoveries.
February 25, 2015
Orca Pharmaceuticals, a BioMotiv portfolio company, and AstraZeneca announced a partnership to develop inhibitors against a wide range of autoimmune diseases. Orca will receive upfront and milestone payments from AstraZeneca with a potential total value of $122.5 million.
February 10, 2015
The second annual Harrington Prize for Innovation in Medicine
has been awarded to oncologist, researcher Douglas R. Lowy, MD, Chief, Laboratory of
Cellular Oncology, and Deputy Director of the National Cancer Institute.
February 2, 2015
BioMotiv, a drug development accelerator associated with The Harrington Project, the University of California San Francisco (UCSF), and University of Washington, Seattle are announcing the formation of OptiKira, a platform company that will develop small molecule therapeutics that prevent cell death in pathologies caused by misfolded or unfolded proteins.
December 9, 2014
The Harrington Discovery Institute at University Hospitals (UH) in
Cleveland, Ohio, has announced the 2015 recipients of Harrington Scholar-Innovator Awards. The
awards will support drug discovery efforts of great promise at renowned institutions across the
November 11, 2014
The Harrington Discovery Institute at University
Hospitals (UH) in Cleveland and University of Oxford (Oxford) in the United Kingdom
announced today a newly formed affiliation that will leverage the academic medical centers’
combined expertise and resources to advance highly
promising drug discovery projects.
October 08, 2014
Two Cleveland families — Gordon and Lulie Gund and the Harrington family of
Hudson — are joining forces to pledge $50 million for finding treatments and cures for people affected
by inherited retinal diseases that lead to blindness.
October 6, 2014
Gund-Harrington Initiative will create the National Center of Excellence in Fighting Blindness as part of the Harrington Discovery Institute at University Hospitals, Cleveland
September 25, 2014
Japan’s biggest pharmaceutical company plans to invest $25 million in BioMotiv, a Shaker Heights company that aims to commercialize all sorts of new drugs. The five-year investment gives Takeda Pharmaceutical Co. the right to make the first offer on any therapies BioMotiv develops related to heart disease, diabetes and other so-called cardiometabolic conditions, as well as any disease involving inflammation and the immune system…BioMotiv is the for-profit arm of the Harrington Project for Discovery and Development. Launched by University Hospitals in 2012, the project includes a nonprofit branch that gives grants to scientists in the early stages of developing new drugs…Takeda has done business in Northeast Ohio before. In 2012, the company made an investment in Juventas Therapeutics, a Cleveland drug developer. That company’s drug — which is designed to trick the body into sending more stem cells to the site of an injury than it otherwise would, thereby speeding up the healing process — showed therapeutic potential during a recent Phase II clinical trial…
July 18, 2014
A 2-year-old University Hospitals project is lowering the imposing barrier of entry for pharmaceutical startup companies.
July 8, 2014
BioCentury Takes Note of Dual Therapeutics BioCentury, the biotech-focused business journal, recently featured Dual Therapeutics in its Emerging Company Profile section. The article focuses on Dual's lead compound, a PP2A activator, which has shown potent in vivo activity across different stages of prostate cancers and could provide a dramatic benefit in cases where anti-androgen drugs do not work.
June 19, 2014
ADDF Harrington Scholars selected to receive funding and project management to support recent discoveries that may lead to new therapeutics for the treatment of Alzheimer’s disease
June 11, 2014
Today the Ohio Third Frontier Commission made the first awards from the new Technology Commercialization Center Program. The two projects that received funding will take breakthrough technologies and turn them into treatments and medicines that will change lives.
June 3, 2014
Watch the video.
May 2, 2014
Dual Therapeutics, an oncology start-up based on technology from a Harrington Scholar and licensed from the Mt. Sinai School of Medicine, announced today an investment from the Partnership Fund for New York City. The company's lead candidate, a small molecule PP2A activator, has demonstrated in vivo efficacy in models of prostate cancer, lung cancer, and acute lymphocytic leukemia. The Partnership funding and BioMotiv’s continuing investment will enable Dual Therapeutics to achieve an IND filing in early 2015.
April 29, 2014
National and international nominations are being sought for the second annual Harrington Prize for Innovation in Medicine, which honors a medical researcher for notable achievements in innovation, creativity and potential for clinical application.
March 18, 2014
The Harrington Discovery Institute (HDI) at University Hospitals (UH) Cleveland Medical Center has opened its third annual grant competition to fund and support physician-scientists at major academic medical centers across the nation in their efforts to accelerate promising drug discoveries.
BioAtla, a global biotechnology company focused on the development of conditionally active biologics (CABs), and BioMotiv, the therapeutics accelerator for The Harrington Project for Discovery & Development, today announced that BioAtla licensed exclusive worldwide rights to BioMotiv to develop and commercialize its TH22 pathway-directed antibody compound for the treatment of inflammatory bowel diseases (IBD) and oncologic indications. In conjunction with the agreement, BioMotiv established Kodosil Bio which will develop all compounds resulting from the license.
Antibodies that prevent the development of Alzheimer's disease...Individualized drugs for prostate cancer....An agent that blocks chronic pain....
February 11, 2014
The inaugural Harrington Prize for Innovation in Medicine has been awarded to pediatric cardiologist and genetics researcher Harry Dietz, MD, of The Johns Hopkins University School of Medicine.
BioMotiv and Harrington Project Model Featured in Nature Article BioMotiv and The Harrington Project are cited as an example of a new model for the funding of promising technologies in a Nature Biotechnology article.
December 10, 2013
Cleveland, Ohio - The Harrington Discovery Institute at University Hospitals (UH) Cleveland Medical Center has announced the 2014 recipients of Harrington Scholar-Innovator Awards. The awards will support drug discovery efforts of great promise at renowned institutions across the nation.
October 24, 2013
Cleveland, Ohio - The Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute at University Hospitals (UH) Cleveland Medical Center announced today a newly formed partnership that will leverage their combined expertise and resources to advance highly promising Alzheimer’s disease drug discovery projects conducted in academic medical institutions nationwide.
October 9, 2013
A $250 million drug discovery initiative launched last year at University Hospitals of Cleveland has produced its second startup, this one based on cancer research from the Icahn School of Medicine at Mount Sinai. Dual Therapeutics will develop new treatments for prostate cancer, lung cancer and acute lymphoblastic leukemia, according to an announcement today from BioMotiv.
September 27, 2013
The gap between basic discovery and clinical introduction is often called the "Valley of Death" because it is the burial ground for a huge number of innovative ideas. Figuring out how to bridge this gap is therefore essential to developing new treatments and cures. Recently, my colleagues and I visited University Hospitals in Cleveland, where we learned about the Harrington Project for Discovery & Development. This initiative supports breakthrough science by providing both financial resources and expert guidance to promote entrepreneurship in medicine…
September 26, 2013
Mukesh Jain, MD, Scientific Director of Harrington Discovery Institute at University Hospitals Cleveland Medical Center, Chief Research Officer of University Hospitals Harrington Heart & Vascular Institute and Director of Case Cardiovascular Research Institute at Case Western Reserve University, shares his insight on generating quality ideas that lead to NIH funding, offers perspective on effectively mentoring young investigators and discusses the future goals of the Harrington Discovery Institute.
September 17, 2013
A local company trying to bring all sorts of new drugs to market has formed a partnership with a nonprofit that aims to find new uses for existing medicines… “Our goal is to develop new medicines for patients as quickly as possible,” said Baiju R. Shah, CEO of BioMotiv… BioMotiv serves as the for-profit arm of the Harrington Project for Discovery & Development. The initiative includes the nonprofit University Hospitals Harrington Discovery Institute, which awards grants to support the development of new drugs.
Monday, September 9, 2013
A local company that aims to help commercialize all sorts of pharmaceuticals has spun off its first startup. BioMotiv LLC of Shaker Heights and New York University have formed Orca Pharmaceuticals, an Oxford, England, company that aims to commercialize an oral drug designed to treat psoriasis and other autoimmune diseases. The technology was developed by investors from the university, in collaboration with founders in England. BioMotiv aims to license the rights to dozens of pharmaceutical technologies from research institutions all over the world, developing and testing them to the point where other investors are willing to buy the rights. The company has raised a total of $46 million from investors since it was founded in mid-2012. BioMotiv serves as the for-profit arm of the Harrington Project for Discovery & Development. The initiative includes the nonprofit University Hospitals Harrington Discovery Institute, which awards grants to support the development of new drugs.
Tuesday, August 13, 2013
BioMotiv and Torrey Pines Investment, a San Diego based specialty life-science investor have signed a multi-million dollar joint investment framework to fund early stage life-science programs and companies over the next seven years.
Friday, May 24, 2013
BioMotiv, a drug development accelerator based in Cleveland, Ohio, today announced that it has increased its total capital from investors to $46 million, adding Nationwide Mutual Insurance Company and several individual investors to its founding investors, University Hospitals of Cleveland and the Harrington Family. Nationwide Mutual Insurance Company also will appoint a representative to serve on the Board of Managers of BioMotiv.
Friday, May 24, 2013
Cancer geneticist: University Hospitals Cleveland Medical Center. From the nomination: Thirteen years ago, Dr. Goutham Narla first discovered the tumor suppressor gene, KLF6, as a medical student at the Mount Sinai School of Medicine in the laboratory of Dr. Scott Friedman. His work in identifying and characterizing key genes and pathways involved in human cancer development and progression — and the development of novel drugs to target these genes in various cancers — was only just beginning. Today a renowned cancer geneticist, Dr. Narla joined University Hospitals Cleveland Medical Center and Case Western Reserve University last year as the first Harrington Distinguished Scholar (Early Career Award). Since coming to Cleveland, he has published two significant studies that have attracted national attention and will have “major impact” on patients with lung and breast cancer…
Tuesday, April 30, 2013
New prize includes $20,000 honorarium; collaboration between ASCI and
Harrington Discovery Institute
Thursday, January 24, 2013
Cleveland - A team of researchers led by Goutham Narla, MD, PhD, at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, and collaborators at the Mount Sinai School of Medicine and Erasmus Medical Center, have discovered a gene variant that drives the spread of breast cancer. Published in Science Translational Medicine (embargoed Jan. 23 at 2:00 pm ET), the study lays the early foundation for predicting which breast cancer patients may develop more aggressive disease and for designing more effective treatments.
Thursday, January 23, 2013
December 27, 2012
December 12, 2012
December 5, 2012
December 4, 2012
November 29, 2012
Harrington InnovationSupport Center